Leerink, Cantor Fitzgerald, Stifel, Oppenheimer and Baird acted as joint book running managers for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXEO:
- Lexeo announces common stock and warrants offering, no amount given
- 3 Best Stocks to Buy Now, 10/15/2025, According to Top Analysts
- Lexeo Therapeutics initiated with a Buy at Guggenheim
- Buy Rating for Lexeo Therapeutics Driven by Regulatory Progress and Promising Clinical Data on LX2006
- Lexeo Therapeutics price target raised to $17 from $15 at Chardan